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Abstract
Introduction: A growing body of evidence supports the usefulness of dysplastic signs detected by flow cytometry in the diagnosis of myelodyspla-
stic syndromes (MDS). Our aim was to assess the impact of pre-analytical variables (delayed sample handling, type of anticoagulant, and different 
clones of antibody) in the interpretation of flow cytometric results.
Material and methods: Bone marrow samples were labelled and analysed immediately after aspiration and on two consecutive days. The effect 
of anticoagulant type was evaluated in 16 bone marrow samples. Thirty-seven different immunophenotypic variables were recorded after eight-co-
lour staining. Furthermore, 8 normal peripheral blood samples collected in K3-EDTA and Na-heparin were examined with different clones of CD11b 
antibodies and four parameters were recorded with both anticoagulants on two consecutive days. 
Results: Fourteen significant differences were detected in the initial immunophenotype of fresh samples collected in K3-EDTA and Na-heparin. Re-
gardless of the anticoagulant type, eleven parameters remained stable despite delayed sample handling. Due to delayed sample processing, more 
alterations were detected in the samples collected in K3-EDTA than in the samples collected in Na-heparin. The type of CD11b clone influenced the 
reduction of fluorescence intensity only in samples collected in K3-EDTA, where the alterations were contrary to the changes observed in Na-heparin. 
Conclusions: Delayed sample processing causes considerable immunohenotypic alterations, which can lead to false interpretation of the results. 
If delayed sample evaluation is unavoidable, markers that remain more stable over time should be considered with more weight in the diagnosis of 
MDS. 
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Introduction
Myelodysplastic syndromes (MDS) are heteroge-
neous clonal hematopoietic stem cell disorders, 
therefore no single specific marker or method ex-
ists for diagnosing all MDS cases. At the same time, 
MDS are characterized by variable clinical out-
come, which makes precise diagnosis and classifi-
cation of cases by prognostic category vital. The 
algorithm currently applied for the diagnosis and 
prognostic classification of MDS considers several 
parameters from morphologic and cytogenetic 
examinations, and in addition, it also recommends 
the application of other methods, such as flow cy-
tometry (FCM) (1). The changes of surface and cy-
toplasmic antigen expression patterns during nor-
mal haematopoiesis are well known (2,3). In the 
past few decades several studies demonstrated 
that there are characteristic alterations compared 
to normal expression patterns which can support 
the diagnosis of MDS or MDS-related acute mye-
loid leukaemia (AML). Relying on the most com-
mon dysplastic signs, several flow cytometry scor-
ing systems (FCSS) have been established, and 
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they proved to be even more sensitive than mor-
phology in detecting dysplasia (4-9). As the feasi-
bility of using FCM for the diagnosis and prognos-
tic classification of MDS got verified, the Interna-
tional/European LeukemiaNet (ELN) Working 
Group for Flow Cytometry in MDS (IMDSFlow) set 
the aim of integrating FCM into the recommenda-
tions of the World Health Organization (WHO) clas-
sification to an even greater extent (10). To reach 
this goal, it is essential to standardize and harmo-
nize the diagnostic and prognostic use of FCM; 
therefore the recommendations issued by ELN 
should be followed strictly.
According to the recent ELN recommendation, the 
immunophenotypic alterations in MDS should be 
analysed within 24 hours, preferably using bone 
marrow (BM) samples collected in heparin, or ethyl-
enediaminetetraacetic acid (K3-EDTA) as an alterna-
tive anticoagulant (11,12). It is evident that delayed 
sample handling leads to apoptosis, then necrosis, 
and it is also known that K3-EDTA and sodium(Na)-
heparin affect cell viability differently: several stud-
ies established that EDTA accelerates apoptosis and 
necrosis of cells (13-15). Apoptotic cells exhibit char-
acteristic changes in the nuclear, cytoskeletal, and 
membrane structure (16,17). These changes often 
result in altered expression patterns of markers 
which resemble dysplastic signs and can cause false 
interpretation. Apoptosis can be avoided or mini-
mized by adhering to the ELN recommendation, 
however, the transportation of samples and the re-
sulting delay in sample handling is inescapable in 
several regional laboratories. 
This practical problem motivated us to examine 
the time-dependent immunophenotypic changes 
of a range of markers on different cell types and 
identify the ones which may be mistaken for dys-
plastic signs. On the other hand – while FCM works 
fine with samples collected in either K3-EDTA or 
Na-heparin – we also wanted to learn how the ap-
plication of one or the other type of anticoagulant 
influenced the expression patterns. Finally, we 
paid special attention to how different anticoagu-
lant types and clones of antibody used for label-
ling affected the expression of CD11b, since previ-
ous studies published contradictory results in this 
respect (18-20).
Materials and methods
Study design
Two groups of participants were selected. In the 
first group twenty-three patients with suspected 
MDS or myeloproliferative neoplasms (MPN) were 
included in a prospective study. They were re-
ferred to the Department of Laboratory Medicine, 
University of Debrecen, Hungary, between De-
cember 2014 and February 2015 for detailed ex-
amination. The clinical and laboratory parameters 
of patients are summarized in Table 1. Three tubes 
of bone marrow samples were collected from each 
patient for diagnostic purposes. One sample was 
collected in K3-EDTA (3.0 mL plastic tubes, ref. 
368857; Becton, Dickinson and Company, BD 
Franklin Lakes, USA) for morphological, flow cyto-
metric and molecular examinations, while two 
tubes in Na-heparin (6.0 mL plastic tubes, ref. 
367876; Becton, Dickinson and Company, BD 
Franklin Lakes, USA) for cytogenetic analysis. We 
performed our experiments on residual samples 
Patients with suspected 
MDS or MPN (N = 23)
Final diagnosis
MDS
MPN
AML
Iron, B12 or folate deficiency
Other (lymphoma, sepsis)
6
4
3
6
4
Age (years) 60 (23 - 87)
Gender (female/male) 11/12
WBC (x109/L) 5.2 (0.74 - 14.4)
Hb (g/L) 103 (64 - 171)
Plt (x109/L) 206 (11 - 568)
ANC (x109/L) 3.3 (0.59 - 9.16)
WBC - white blood cell count. Hb – haemoglobin. Plt - platelet 
count. ANC - absolute neutrophil count. MDS - myelodysplastic 
syndromes. MPN - myeloproliferative neoplasms. AML - acute 
myeloid leukaemia. The final diagnosis of patients was based 
on laboratory parameters (e.g. B12, folic acid concentrations) 
as well as morphological, cytogenetic, and flow cytometric 
examination. WBC, Hb, Plt and ANC parameters were measured 
in peripheral blood samples of patients with suspected MDS or 
MPN.
Table 1. Clinical and laboratory parameters of patients
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that remained after the diagnostic tests. To exam-
ine the effect of the different anticoagulants, we 
evaluated the de novo immunophenotype and its 
alterations on day 1 and day 2 in samples collected 
into K3-EDTA (N = 23) or Na-heparin (N = 16). Sam-
ples were kept on room temperature prior to anal-
ysis.
In the second group residual peripheral blood (PB) 
samples of eight patients with no haematological 
malignancy were collected in one tube K3-EDTA 
and one tube Na-heparin for flow cytometry 
measurements, and they were examined with dif-
ferent clones of CD11b monoclonal antibodies. 
We conducted our studies in compliance with the 
principles of the Declaration of Helsinki. Informed 
consent was obtained from each participant. The 
Hungarian Medical Research Council granted per-
mission for our studies (20582-2/2017/EKU). 
Methods
Bone marrow samples were analysed for MDS by 
eight-colour labelling. The antibodies and clones 
we examined are shown in Table 2. CD14, CD11b, 
HLA-DR, CD45, CD64, CD13, CD15, CD34, CD71, 
CD117, CD300e, CD4, and CD10 markers were pur-
chased from Becton Dickinson Biosciences (San 
Jose, USA); CD33, CD16, and CD13 markers were 
purchased from Beckman Coulter, (Brea, USA); 
CD45 marker was purchased from Invitrogen 
(Thermo Scientific Inc., Walthman, USA); and HLA-
DR marker was purchased from Biolegend (San 
Diego, USA). Antibody combinations were added 
to 50 mL BM or PB samples (1 x 106 cells) and incu-
bated for 15 minutes in the dark at room tempera-
ture. Then 1 mL lysing solution was added to each 
tube and samples were incubated for an addition-
al 8 minutes. Finally, samples were washed once in 
Fluorochrome
Antibody combination (volume)
MDS diagnosis
FITC CD14 (30x) MoP9 (6 μL) CD15 (20x) MMA (6 μL) CD71 (16x) LO1.1 (6 μL)
PE CD11b (D12) (6 μL) 123 (SSDCLY107D2) (6 μL) CD117 (104D2) (6 μL)
PerCP-Cy5.5/PC5.5 HLA-DR (L243) (5 μL) CD34 (8G12) (5 μL) CD33 (16x) (D3HL60.251) (5 μL)
PC7 CD13 (Immu 103.4) (5 μL) CD13 (Immu 103.4) (5 μL) CD56 (N901) (5 μL)
APC CD300e (UP H2) (2.5 μL) CD10 (HI10a) (2.5 μL) CD34 (581) (2.5 μL)
APC-AF750 CD64 (2x) (22) (2.5 μL) CD16 (30x) (3G8) (5 μL) CD38 (HB7) (2.5 μL)
PB CD4 (16x) (RPA-T4) (5 μL) HLA-DR (L243) (1 μL) CD7n (8H8.1) (2.5 μL)
PO CD45 (4x) (HI30) (2.5 μL) CD45 (4x) (HI30) (2.5 μL) CD45 (4x) (HI30) (2.5 μL)
Intensity of CD11b expression
FITC - CD11b (ICRF44) (6 μL) -
PE CD11b (D12) (6 μL) - -
PerCP-Cy5.5/PC5.5 CD33 (16x) (D3HL60.251) (5 μL) CD33 (16x) (D3HL60.251) (5 μL) -
PC7 CD13 (Immu 103.4) (5 μL) CD13 (Immu 103.4) (5 μL) -
APC CD10 (HI10a) (2.5 μL) CD10 (HI10a) (2.5 μL) -
APC-AF750 CD64 (2x) (22) (2.5 μL) CD64 (2x) (22) (2.5 μL) -
PB HLA-DR (L243) (1 μL) HLA-DR (L243) (1 μL) -
PO CD45 (4x) (HI30) (2.5 μL) CD45 (4x) (HI30) (2.5 μL) -
MDS – myelodysplastic syndromes. On the basis of the upper panel, not only different cell types can be identified but the 
characteristic MDS-related signs can also be detected. The intensity of CD11b expression was examined with the help of the lower 
panel. Monocytes and granulocytes were differentiated on the basis of their side scatter character and CD33, CD64, CD45, and 
HLA-DR expression. 
Table 2. Antibody combinations used in flow cytometric examination for the diagnosis of MDS
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phosphate-buffered saline (PBS) and suspended in 
500 mL 1% paraformaldehyde (PFA). The FACS 
Canto II flow cytometer (Becton Dickinson Bio-
sciences, San Jose, USA) was used for cell analysis. 
To make the results comparable, the flow cytome-
ter was calibrated daily, using Cytometer Setup 
and Tracking fluorescent microbeads (Cat No. 
641319, Becton Dickinson Biosciences, San Jose, 
USA) and Autocomp software as recommended 
by the manufacturer. Data were analysed by FACS 
Diva version 6.1.3 (Becton Dickinson Biosciences, 
San Jose, CA, USA) and Kaluza Softwares version 
1.2 (Beckman Coulter, Brea, CA, USA).
In case of MDS examinations, the gating strategy 
was the following: the first step was elimination of 
debris with the help of forward scatter (FSC) and 
side scatter (SSC) bivariate dot plot. Myeloblasts 
(MBs, CD117+/CD34+/SSCint) and lymphoblasts 
(LBs, CD117-/CD34+/SSClow) were identified on 
the basis of SSC character, CD117 and CD34 mark-
ers; then CD45 was applied in the last step, back 
gating. Depending on the SSC character and the 
intensity of CD45, CD33, CD64, or HLA-DR expres-
sion, cells were identified as lymphocytes, mono-
cytes, and granulocytes. CD71+/CD45- cells were 
classified as erythroid precursors. As for rare 
events, plasma cells (PCs, CD38 bright) were in-
cluded in our study (3).
Thirty-seven different immunophenotypic varia-
bles were recorded for the samples collected in 
K3-EDTA and those ones in Na-heparin for three 
days (de novo = day 0, day 1 and day 2), of which 
mean fluorescence intensity (MFI) values, robust 
coefficient of variation (rCV) and percentages of 
different cell types were calculated daily com-
pared to de novo values.
In the second part of our study, we investigated 
not only the impact of using different anticoagu-
lants on time-dependent changes of CD11b ex-
pression on granulocytes and monocytes but also 
the consequence of using different antibody 
clones (Table 2). Fluorescein isothiocyanate (FITC) 
labelled CD11b (clone: ICRF44) was purchased 
from Sigma Aldrich (Saint Louis, USA), while phy-
coerythrin (PE) labelled CD11b (D12) was pur-
chased from Becton Dickinson Biosciences (San 
Jose, USA). The gating strategy was the following: 
the first step was elimination of debris with the 
help of FSC and SSC bivariate dot plot. Granulo-
cytes and monocytes were differentiated on the 
basis of their SSC character and CD33, CD64, CD45, 
and HLA-DR intensity. Four parameters were re-
corded: CD11b MFI of the two different antibody 
clones labelled by different fluorochromes on 
monocytes and granulocytes in K3-EDTA and in 
Na-heparin right after blood drawing and on two 
consecutive days. 
Statistical analysis
Considering the low number of samples non-para-
metric tests were used. Two related groups were 
compared by Wilcoxon signed-rank test. P < 0.05 
was considered statistically significant. In case of 
time-dependent immunophenotypic changes, 
where there were more than two related groups, 
data were analysed by Friedman test. Dunn’s mul-
tiple comparison test was applied as post hoc test. 
Statistical analysis and the creation of figures were 
carried out using SPSS 20.0 (SPSS 20.0, Chicago, 
USA) and GraphPad Prism 6.0 (GraphPad Software, 
San Diego, USA) statistical programs.
Results
Comparison of FCM parameters of samples 
collected in K3-EDTA and Na-heparin at day 0
When we compared the initial immunophenotype 
of fresh samples collected in K3-EDTA and Na-hep-
arin, we detected significant differences in four-
teen parameters indicated in Table 3. 
Six parameters were significantly higher in sam-
ples collected in K3-EDTA as compared to samples 
collected in Na-heparin: MFI of CD4 on mono-
cytes, MFI of CD117 on MBs, MFI of CD45 on lym-
phocytes, rCV of CD71 on erythroid precursors 
and percentage and MFI of CD38 on PCs. 
Eight parameters were significantly lower: SSC and 
intensity of CD45, CD11b and CD33 expression on 
granulocytes, MFI of CD11b, CD13 on monocytes, 
MFI of CD34 on MBs and MFI of CD71 on erythro-
blasts. Despite significant alterations in the CD34, 
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Cell population Marker
Mean fluorescence intensity rates
P
Na-heparin K3-EDTA
Granulocyte
(N = 16)
SSC 160,346 (133,356 - 177,111) 146,635 (129,971 - 153,327) 0.003
CD45 3964 (3271 – 4569) 3113 (2696 – 4324) 0.013
CD15 5743 (4329 – 6828) 6803 (4177 – 7924) 0.134
HLA-DR 179 (93 – 390) 243 (197 – 286) 0.155
CD11b 10,389 (7208 - 14,936) 1990 (1593 – 3299) < 0.001
CD13 1754 (1398 – 2576) 1786 (1102 – 2288) 0.079
CD16 1764 (1342 – 2119) 1755 (1395 – 2878) 0.836
CD10 1215 (977 – 1641) 931 (801 – 1692) 0.179
CD33 1334 (992 – 1670) 1194 (878 – 1705) 0.044
CD16% 45.5 (40.1 - 61.3) 47.5 (38.0 - 58.9) 0.641
CD10% 34.5 (29.2 - 49.5) 34.9 (31.5 - 54.3) 0.733
Monocyte
(N = 16)
SSC 75,758 (68,211 - 80,506) 73,891 (67,578 - 80,301) 0.125
CD64 1330 (1140 – 2051) 1584 (1105 – 2368) 0.776
CD4 455 (369 – 543) 496 (323 – 753) 0.036
CD15 1072 (799 – 1502) 1114 (987 – 1528) 0.433
HLA-DR 7178 (4578 – 7955) 6165 (4420 – 7139) 0.078
CD11b 13,545 (11,385 - 20,306) 4001 (3453 – 5080) 0.001
CD13 3522 (1339 – 7092) 3322 (1106 – 4792) 0.031
CD14 889 (812 – 1482) 971 (720 – 1254) 0.078
CD300e 1052 (724 – 1914) 1070 (789 – 1804) 0.955
CD33 7086 (5827 – 9495) 6790 (5119 – 8390) 0.078
CD14% 55.4 (41.3 - 62.5) 57.3 (47.8 - 62.8) 0.842
CD300e% 39.1 (24.2 - 58.8) 41.5 (26.0 - 59.0) 0.272
Myeloblast 
(N = 16)
% 0.88 (0.62 - 2.30) 1.06 (0.73 - 2.08) 0.451
CD45 3571 (3019 – 3951) 3581 (2820 – 3938) 0.877
CD34 3017 (2276 – 4231) 2495 (1959 – 3125) 0.008
CD117 2599 (2178 – 5455) 3321 (2805 – 5956) 0.001
Lymphoblast (N = 7) % 0.10 (0.06 - 0.20) 0.08 (0.06 - 0.16) 0.061
PreB cell (N = 9) CD10% 0.50 (0.25 - 0.95) 0.90 (0.40 - 1.11) 0.172
Lymphocyte
(N = 16)
% 9.70 (6.25 - 15.45) 10.30 (6.03 - 14.88) 0.82
SSC 20,777 (19,017 - 21,783) 20,427 (18,451 - 21,907) 0.352
CD45 15,833 (12,913 - 18,175) 16,742 (13,839 - 21,026) 0.004
Erythroid precursor
(N = 16)
% 18.80 (10.33 - 31.25) 19.40 (11.83 - 31.25) 0.776
CD71 6158 (3767 – 8283) 3564 (2201 – 5261) 0.003
CD71rCV 79.5 (53.8 - 112.3) 102.7 (81.0 - 117.7) 0.049
Plasma cell
(N = 15)
% 0.2 (0.2 - 0.5) 0.5 (0.3 - 0.9) 0.005
CD38 29,173 (25,738 - 32,208) 35,393 (29,221 - 38,793) 0.002
SSC - side scatter. Mean fluorescence intensity values and percentages (%) are presented as median and interquartile range. The 
number of cases by cell population is different because certain cell types were not detectable in all samples (sensitivity: 0.03). 
The groups (K3-EDTA and Na-heparin) were compared by Wilcoxon signed-rank test. P < 0.05 values were considered statistically 
significant.
Table 3. Immunophenotype changes caused by K3-EDTA compared to the Na-heparin sample on day 0 in bone marrow samples
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CD117 and CD71 expression, the percentage of 
MBs, LBs or erythroid precursors did not show sig-
nificant differences between the samples collect-
ed in K3-EDTA and Na-heparin, so these alterations 
did not influence the appropriate gating of the dif-
ferent cell types. 
Immunophenotypic alterations of bone 
marrow samples caused by delayed sample 
handling 
Due to delayed sample processing ten parameters 
were significantly altered by day 1 in samples col-
lected in K3-EDTA, while in samples collected in 
Na-heparin only four parameters changed (Table 
4). Two of these (the MFI of CD117 on MBs and the 
MFI of CD38 on PCs) proved to be the most sensi-
tive for delayed sample processing. Regardless of 
the type of anticoagulant, the intensity of these 
markers fell continuously during the time of obser-
vation. 
On top of the day 1 changes, similar number of ad-
ditional alterations were detected by day 2 in the 
cases of samples collected in Na-heparin and K3-
EDTA. Fifteen parameters in scope decreased sig-
nificantly in samples collected in K3-EDTA, while 
three parameters increased and twelve parame-
ters decreased in samples collected in Na-heparin. 
Nine parameters changed by day 2 regardless of 
the type of anticoagulant: the SSC on granulo-
cytes, the MFI of CD4, CD64, CD33 on monocytes 
and the ratio of CD14 positive monocytes, the per-
centage of preB cells and lymphocytes, the MFI of 
CD45 on lymphocytes and the MFI of CD71 on 
erythroid precursors. 
Figure 1. Alterations of CD11b expression on peripheral blood granulocytes caused by delayed sample handling (N = 8). A and B 
represent samples collected in Na-heparin, C and D represents samples collected in K3-EDTA. A and C represent FITC-labelled CD11b, 
while B and D represent PE-labelled CD11b. The groups were compared by Friedman test. Dunn’s multiple comparison test was ap-
plied as post hoc test.
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Table 4. Time-dependent immunophenotype changes in bone marrow samples collected with K3-EDTA and Na-heparin
Tube 
type Cell population Marker
Mean fluorescence intensity rates
P1 P2
day 0 day 1 day 2
K
3-
ED
TA
Granulocyte
(N = 23)
SSC 153,327 (138,520 – 176,341) 149,831 (134,405 – 172,463) 124,668 (110,787 - 148,576) > 0.999 < 0.001
CD45 3000 (2739 – 3753) 4141 (3313 – 4472) 3610 (2787 – 3972) 0.037 > 0.999
CD15 3900 (2199 – 7126) 4681 (2203 – 6913) 3734 (2473 – 6290) > 0.999 0.554
HLA-DR 235 (185 – 285) 269 (233 – 341) 324 (261 – 452) 0.037 < 0.001
CD11b 2795 (1709 – 3613) 1566 (887 – 2406) 642 (436 – 1082) 0.117 < 0.001
CD13 1845 (1185 – 2308) 2538 (1875 – 3073) 2607 (2162 – 3296) 0.006 0.001
CD16 2179 (1491 – 2930) 2102 (1750 – 3000) 1780 (1003 - 2727) 0.554 0.554
CD10 1183 (847 – 1627) 1178 (1001 – 1768) 976 (807 - 1285) 0.231 0.231
CD33 1212 (815 – 1717) 1349 (917 – 1773) 1188 (754 – 1678) 0.055 > 0.999
CD16% 49.0 (42.0 - 60.8) 51.0 (43.0 - 56.2) 50.0 (40.7 - 59.0) 0.029 0.715
CD10% 38.1 (31.0 - 47.0) 41.0 (34.4 - 49.5) 38.4 (31.7 - 45.0) 0.081 > 0.999
Monocyte
(N = 23)
SSC 79,099 (71,934 - 83,805) 68,674 (64,864 - 75,911) 62,401 (60,160 - 67,200) 0.117 < 0.001
CD64 1596 (1107 – 1886) 1441 (1052 – 1757) 973 (732 – 1544) 0.117 < 0.001
CD4 579 (422 – 691) 512 (341 – 712) 418 (324 – 552) > 0.999 0.024
CD15 967 (280 – 1290) 632 (281 – 836) 564 (309 – 924) 0.081 0.024
HLA-DR 6320 (5487 – 7790) 5779 (4291 – 10,731) 5109 (3969 – 7598) > 0.999 0.315
CD11b 4700 (3712 – 6538) 716 (342 – 1026) 325 (209 – 406) < 0.001 < 0.001
CD13 4190 (1403 – 6409) 2873 (1156 – 5090) 2928 (2035 – 4448) 0.006 0.024
CD14 1121 (777 – 1571) 777 (627 – 1023) 556 (377 – 718) 0.037 < 0.001
CD300e 1423 (1055 – 1787) 767 (556 – 1263) 523 (379 – 925) 0.081 < 0.001
CD33 6747 (5015 – 8633) 5270 (3750 – 8869) 4045 (3101 – 5355) > 0.999 < 0.001
CD14% 60.0 (50.0 - 65.8) 53.0 (40.0 - 59.0) 25.0 (17.0 - 44.0) 0.231 < 0.001
CD300e% 43.4 (26.5 - 56.0) 31.3 (25.0 - 47.0) 27.7 (13.1 - 36.0) 0.037 < 0.001
Myeloblast
(N = 23)
% 0.92 (0.73 - 1.47) 0.81 (0.54 - 1.35) 0.76 (0.57 - 0.97) 0.196 0.008
CD45 3555 (2383 – 3838) 3242 (2286 – 3992) 3034 (2636 – 4113) 0.421 0.315
CD34 3023 (2262 – 3709) 2976 (1987 – 3484) 2318 (1829 – 3860) 0.554 0.231
CD117 3148 (2781 – 3745) 2411 (2128 – 3523) 1876 (1532 – 2592) 0.006 < 0.001
Lymphoblast
(N = 12) %
0.17 (0.06 - 0.23) 0.15 (0.05 - 0.17) 0.09 (0.06 - 0.16) 0.554 0.459
PreB cell
(N = 17) CD10%
0.90 (0.23 - 1.64) 0.50 (0.19 - 1.02) 0.40 (0.16 - 0.70) 0.215 < 0.001
Lymphocyte
(N = 23)
% 10.9 (6.6 - 16.2) 10.0 (5.7 - 14.7) 8.3 (4.9 - 12.8) 0.554 < 0.001
SSC 21,410 (19,704 - 22,477) 19,611 (17,655 - 20,994) 18,366 (16,682 - 19,817) 0.055 < 0.001
CD45 15,962 (14,646 - 19,342) 14,898 (12,197 - 17,206) 13,087 (9894 - 16,167) 0.081 < 0.001
Erythroid 
precursor
(N = 23)
% 14.3 (9.2 - 27.7) 14.1 (10.0 - 29.0) 13.9 (9.4 - 28.0) 0.715 > 0.999
CD71 4896 (2448 – 6486) 3164 (1888 – 4449) 2486 (1792 – 3552) 0.315 0.015
CD71rCV 95 (80 - 108.9) 88.9 (68.7 - 113.2) 84.4 (63 - 103.4) > 0.999 > 0.999
Plasma cell
(N = 22)
% 0.50 (0.32 - 0.70) 0.50 (0.30 - 0.63) 0.46 (0.30 - 0.74) 0.457 > 0.999
CD38 36,019 (31,070 - 39,660) 28,946 (24,769 - 33,504) 25,467 (21,210 - 31,042) 0.001 < 0.001
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Table 4. Time-dependent immunophenotype changes in bone marrow samples collected with K3-EDTA and Na-heparin (continued)
N
a 
- h
ep
ar
in
Granulocyte
(N = 16)
SSC 160,346 (133,356 – 177,111)
146,104 (125,819 – 
176,537)
129,252 (109,198 - 
163,244) > 0.999 0.004
CD45 3964 (3271 – 4569) 4680 (3576 – 5277) 4039 (3437 – 4859) 0.335 > 0.999
CD15 5743 (4329 – 6828) 5245 (3720 – 6371) 4398 (2832 – 5335) 0.867 0.024
HLA-DR 179 (93 – 390) 197 (118 - 302) 290 (171 – 492) > 0.999 0.024
CD11b 10,389 (7208 – 14,936) 11,877 (9311 – 16,119) 10,517 (7569 - 13,451) 0.867 > 0.999
CD13 1754 (1398 - 2576) 2218 (1641 - 2680) 2111 (1869 - 3250) 0.648 0.008
CD16 1764 (1342 – 2119) 1939 (1229 – 2618) 1467 (643 – 2142) > 0.999 0.102
CD10 1215 (977 – 1641) 1222 (924 – 1805) 997 (667 - 1341) 0.867 0.335
CD33 1334 (992 – 1670) 1531 (1071 – 1891) 1403 (932 – 1827) 0.472 > 0.999
CD16% 46 (40 – 61) 47 (38 – 59) 40 (31 – 52) > 0.999 0.014
CD10% 35 (29 – 50) 37 (30 – 49) 36 (25 – 46) > 0.999 0.752
Monocyte
(N = 16)
SSC 75,758 (68,211 - 80,506) 76,178 (70,576 - 81,870) 72,624 (66,219 - 81,805) > 0.999 > 0.999
CD64 1330 (1140 – 2051) 1434 (898 - 1966) 1369 (808 – 1803) 0.156 < 0.001
CD4 455 (369 – 543) 344 (276 - 590) 261 (208 – 421) 0.335 < 0.001
CD15 1072 (799 - 1502) 751 (593 - 1249) 681 (496 – 829) 0.024 < 0.001
HLA-DR 7178 (4578 - 7955) 8003 (4743 – 11,516) 7402 (5690 – 8140) 0.472 > 0.999
CD11b 13,545 (11,385 - 20,306) 10,174 (7165 – 12,797) 7428 (4317 – 12,032) 0.232 < 0.001
CD13 3522 (1339 – 7092) 2859 (1195 – 5494) 2559 (1530 - 4105) 0.335 0.867
CD14 889 (812 – 1482) 878 (650 – 1008) 637 (545 – 907) > 0.999 0.014
CD300e 1052 (724 – 1914) 1116 (708 – 1528) 783 (644 – 1273) 0.867 > 0.999
CD33 7086 (5827 – 9495) 5658 (4675 – 8438) 4443 (3817 – 5897) 0.232 < 0.001
CD14% 55.4 (41.3 - 62.5) 50.5 (38.8 - 59.8) 36.5 (22.3 - 45.5) > 0.999 < 0.001
CD300e% 39.1 (24.2 - 58.8) 41.9 (24.5- 50.8) 32.0 (24.0 - 52.3) > 0.999 > 0.999
Myeloblast
(N = 16)
% 0.88 (0.62 - 2.30) 0.74 (0.50 - 1.95) 0.73 (0.42 - 2.12) 0.279 0.065
CD45 3571 (3019 – 3951) 3554 (2594 – 4571) 3484 (2780 – 4096) > 0.999 > 0.999
CD34 3017 (2276 – 4231) 2624 (1535 – 3053) 2137 (1680 – 2812) 0.335 0.102
CD117 2599 (2178 – 5455) 1973 (1355 – 3308) 1524 (1186 – 2572) 0.004 < 0.001
Lymphoblast
(N = 8)
% 0.09 (0.05 - 0.18) 0.07 (0.03 - 0.14) 0.07 (0.02 - 0.10) > 0.999 0.508
PreB cell
(N = 9)
CD10% 0.50 (0.25 - 0.95) 0.52 (0.25 - 0.85) 0.30 (0.17 - 0.70) > 0.999 0.001
Lymphocyte
(N = 16)
% 9.7 (6.3 - 15.5) 7.7 (4.5 - 13.2) 6.9 (3.3 - 10.0) 0.279 0.001
SSC 20,777 (19,017 - 21,783) 17,295 (15,546 - 20,467) 17,232 (15,318 - 18,176) 0.024 < 0.001
CD45 15,833 (12,913 - 18,175) 12,204 (9853 - 17,172) 9948 (8465 -14,071) 0.472 0.002
Erythroid 
precursor
(N = 16)
% 18.8 (10.3 - 31.3) 20.1 (10.8 - 31.5) 19.2 (10.4 - 33.8) > 0.999 0.867
CD71 6158 (3767 – 8283) 4367 (2268 - 7238) 3479 (2233 – 7007) 0.156 0.002
CD71rCV 79.5 (53.8 - 112.3) 82.1 (67.5 - 114.3) 80.9 (61.3 - 107.3) > 0.999 > 0.999
Plasma cell
(N = 15)
% 0.20 (0.20 - 0.50) 0.20 (0.10 - 0.50) 0.30 (0.10 - 0.50) 0.166 > 0.999
CD38 29,173 (25,738 - 32,208) 19,312 (17,781 - 27,495) 17,022 (14,953 - 18,877) 0.032 < 0.001
SSC - side scatter. Mean fluorescence intensity values and percentages (%) are presented as median and interquartile range. P1 
- comparison of day 0 and day 1 results. P2 - comparison of day 0 and day 2 results. The number of cases by cell population is 
different because certain cell types were not detectable in all samples (sensitivity: 0.03). The groups were compared by Friedman 
test. Dunn’s multiple comparison test was applied as post hoc test. P < 0.05 values were considered statistically significant.
https://doi.org/10.11613/BM.2018.020704 Biochem Med (Zagreb) 2018;28(2):020704 
  9
Kárai B. et al. Preanalytical factors in flow cytometry
The number of stable markers throughout the 
2-day period was 12 in samples collected in K3-ED-
TA as compared to 18 in samples collected in Na-
heparin. The following eleven parameters were 
the most stable regardless of the type of anticoag-
ulant: MFI of CD16, CD10, CD33 on granulocytes, 
the percentage of CD10 positive granulocytes, 
HLA-DR on monocytes, MFI of CD45 and CD34 on 
MBs, the percentage of LBs, erythroid precursors 
and PCs and the rCV of CD71 on erythroid precur-
sors. 
Immunophenotypic changes of CD11b 
caused by delayed sample handling 
The intensity of PE-labelled CD11b (clone D12) ex-
pression was significantly reduced both on granu-
locytes (Figure 1D) and monocytes (Figure 2D) in 
samples collected in K3-EDTA by day 2. This de-
crease was significant in the case of FITC-labelled 
CD11b (clone ICRF44) only on monocytes (Figure 
2C) by day 2. In samples collected in Na-heparin, 
delayed sample handling caused the opposite 
phenomenon. Regardless of the type of CD11b 
clone, the intensity of CD11b expression of granu-
locytes increased significantly by day 2 in Na-hep-
arin (Figure 1A and 1B). This elevation was signifi-
cant not only on granulocytes but also on mono-
cytes in the case of FITC-labelled CD11b (clone 
ICRF44) by day 2 (Figure 2A). 
Discussion
The most important finding of our study was that 
the type of anticoagulant significantly influenced 
not only the rate and number of alterations caused 
by delayed sample handling but also initial expres-
sion patterns, where apoptotic cells were absent 
or were only minimally present. The expression 
patterns of various cell types proved to be more 
Figure 2. Alterations of CD11b expression on peripheral blood monocytes caused by delayed sample handling (N = 8). A and B repre-
sent samples collected in Na-heparin, C and D represent samples collected in K3-EDTA. A and C represent FITC-labelled CD11b, while 
B and D represent PE-labelled CD11b. The groups were compared by Friedman test. Dunn’s multiple comparison test was applied as 
post hoc test.
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stable in samples collected in Na-heparin, which 
supports the recommendation of European Leu-
kemiaNet regarding the preferred type of antico-
agulant (11,12). However, there were some param-
eters which were altered significantly even by day 
1 in samples collected in Na-heparin. In our study, 
several parameters changed due to delayed sam-
ple processing, and unless the examiner is familiar 
with the extent and direction of such alterations, 
they could be misinterpreted as dysplastic signs. 
This can lead to false diagnosis of MDS, or the as-
signment of already established MDS cases to 
overly advanced stages.
To the best of our knowledge, we were the first to 
examine a wide range of markers on different cell 
types by eight-colour labelling FC method. Previ-
ous studies usually focused on the myeloid popu-
lation and examined a certain marker or only a 
handful of markers. There is an agreement that 
some parameters, consistently changed regardless 
of the type of anticoagulant. One such parameter 
was the decrease in SSC of granulocytes due to 
apoptosis, which can be confirmed by morpholog-
ical examination (15). Reduced CD16, CD43 and in-
creased CD45 expression was detected on apop-
totic myeloid cells even in isolated white blood 
cells from citrated, heparinized or EDTA-anticoag-
ulated whole blood (18,20,21). In contrast to the 
agreement about the behaviour of these markers 
in the literature, contradictory findings have been 
published about the effects of apoptosis caused 
by delayed sample handling on the intensity of 
CD11b expression: some studies detected a rise in 
this antigen expression, while others found loss of 
CD11b (21-23). These results typically depend on 
the design of each study. Because the CD11b pro-
tein is stored in cytoplasmic granules, the intensity 
of this marker can markedly increase during acti-
vation of neutrophils (24). Therefore the first cause 
which can influence the results is the activation of 
neutrophils. This may happen during sample pro-
cessing (purified polymorphonuclear cell, trig-
gered apoptosis) (25). However, the results of the 
study published by Saxton et al. suggest that the 
root cause of activation is not always obvious (26). 
They examined six peripheral whole blood sam-
ples anticoagulated in EDTA with or without cell 
stabilization solution (Cyto-Chexe). They found 
that the intensity of CD11b expression increased in 
the case of samples without cell stabilization solu-
tion at room temperature during the examined 
period (4 hour). In contrast, Hodge et al. found that 
Annexin V staining, which can bind to the cell 
membrane externalized phosphatidylserine (PS) in 
apoptotic cells, was detected only after 6 hours 
(15). This result suggests that the increased CD11b 
expression detected by Saxton et al. on non-stabi-
lized and non-triggered cells was not caused by 
apoptosis but rather spontaneous externalization 
of intracellular CD11b to the cell membrane. So be-
fore or during apoptosis the impact of activation 
should be considered. 
We found that CD11b expression changed in dif-
ferent directions over time, depending on the type 
of anticoagulant: it was over-expressed in samples 
collected in Na-heparin but decreased in samples 
collected in K3-EDTA. Our results confirmed a sec-
ond cause which can influence the change of 
CD11b expression during sample processing, 
namely, the type of the anticoagulant. Not only 
cell viability is affected by the type of anticoagu-
lant but also the binding of the antibody to the an-
tigen. Repo et al. found that the reason why the 
type of anticoagulant was able to influence the 
time-dependent alterations was that CD11b anti-
bodies with D12 clones require divalent cations to 
bind (27). Our results support this explanation, as 
the MFI values were considerably lower in the 
presence of the cation chelator EDTA compared to 
samples drawn into heparin already on day 0 and 
decreased abruptly by day 1. Other CD11b clones 
(ICRF44) showed less of a reduction, and the type 
of clone did not influence the results in the case of 
samples collected in Na-heparin. 
Furthermore, according to our results, the time-
dependent changes of CD11b expression depend 
on sample type. In bone marrow samples CD11b 
expression on granulocytes did not change in 
samples collected in Na-heparin, and it decreased 
significantly on monocytes. In contrast, it in-
creased significantly on granulocytes and mono-
cytes in the peripheral blood samples anticoagu-
lated with Na-heparin. This difference can be ex-
plained by the fact that the two examined cell 
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population (neutrophils from peripheral blood 
and bone marrow) consist of different types of 
cells with differing amounts of granules and intra-
cellular CD11b storage. On the one hand, normal 
peripheral blood contains only mature myeloid 
cells, while bone marrow also contains immature 
variants. On the other hand, all our peripheral 
blood samples were normal, while some of the 
bone marrow samples were pathological. 
The majority of markers we examined were not 
previously included in the studies focusing on the 
impact of pre-analytical variables. Among these 
markers, probably the most important was the 
MFI of CD117, which was altered with both types of 
anticoagulant. Besides CD34 and CD45, CD117 is 
routinely used as a gating marker for determining 
MB count, which is currently the only FCM-based 
parameter included in the recommendations of 
the WHO classification (28). Despite the obviously 
diminished intensity of CD117 in all samples on 
day 1 and day 2, the percentage of MBs was stable 
by day 1 and altered significantly only by day 2 in 
samples collected in K3-EDTA.  
The recently published sensitive and specific Flow 
Cytometric Scoring System enables FCM to poten-
tially play a larger role in the diagnostic and prog-
nostic work-flow of MDS (4-9). Flow cytometry can 
support not only the diagnosis of advanced cases 
– where there are excess blasts – but also helps in 
the identification of low-grade cases. For screen-
ing purposes, the Ogata score can be used, which 
contains only four parameters: percentage of MBs 
in all nucleated cells (MB%), percentage of CD34+ 
LB in CD34 positive cells, granulocytes SSC/lym-
phocytes SSC and lymphocyte/MB CD45 MFI ratio 
(8). All parameters suggested by Ogata et al. 
proved to be stable despite a one-day delay in 
sample handling regardless of the type of antico-
agulant. Only the MB percentage decreased signif-
icantly by day 2 in samples collected in K3-EDTA. 
Percentage of CD34+ LB in CD34 positive cells was 
stable in both anticoagulants. The other two pa-
rameters (granulocytes SSC/ lymphocytes SSC and 
lymphocyte/MB CD45 MFI ratio) were adjusted to 
lymphocytes, which made up the internal control 
population. In our study, the SSC of both granulo-
cytes and lymphocytes decreased significantly by 
day 2 regardless of the type of anticoagulant. The 
MFI of CD45 on MBs was a stable marker, while the 
MFI of CD45 on lymphocytes decreased signifi-
cantly with both types of anticoagulants by day 2, 
which resulted in significant difference in the ratio 
as well and could cause false interpretation of re-
sults on day 2. 
Recently a number of studies focused on non-my-
eloid cell populations like erythroid precursors 
(6,7). Although reduced MFI of CD71 was detected 
in samples collected in either Na-heparin or K3-ED-
TA at day 2, this did not influence the percentage 
of the erythroid precursors. Furthermore, regard-
less of the type of anticoagulant, the CD71 rCV, the 
percentage of LBs, and the MFI of CD45, CD34 on 
MBs and MFI of HLA-DR on monocytes did not dif-
fer significantly even on day 2, which is important 
because FCS systems rely on several of them 
(6,8,29).
It must be acknowledged that there are several 
limitations to the present study. We wanted to ex-
amine a homogenous population, but due to the 
heterogeneous nature of MDS, the patients en-
rolled with suspected MDS/MPN often ended up 
with a different final diagnosis. However, the de-
tection of dysplastic signs play a key role not only 
in the diagnosis of MDS but also in MPN or AML; 
false interpretation of dysplastic signs on normal 
cells due to delayed sample processing can cause 
misdiagnosis of these cases. Furthermore, AML 
with myelodysplasia-related changes, which is an 
independent entity in the WHO classification, is as-
sociated with poor prognosis. Therefore the de-
tection of dysplastic signs on normal cells or blast 
population is also important because it influences 
the treatment. Finally, we could only examine a 
limited number of cases; therefore further studies 
with larger samples will be needed to validate our 
results.  
In conclusion, we examined thirty-seven parame-
ters on myeloid, erythroid and lymphoid popula-
tions, including mature and immature cell popula-
tions. We have already detected alterations in the 
initial immunophenotype depending on the type 
of anticoagulant. Because dysplastic signs are 
identified as alterations compared to the normal 
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pattern, the type of the anticoagulant should al-
ways be considered when comparing the samples 
to the patterns of normal samples. Thus for ease of 
reference, we recommend that only a single type 
of anticoagulant is used in any given laboratory. 
The pre-analytical error of delayed sample pro-
cessing can cause considerable immunopheno-
typic alterations, which can lead to the post-ana-
lytical error of false interpretation of the results. 
Therefore we recommend well-defined standards 
for sample handling to avoid delays. If the sample 
needs to be transported to a regional laboratory 
and delayed sample processing is inescapable, 
then heparin should be the preferred anticoagu-
lant for flow cytometry, and more stable markers 
should be weighted more heavily in the diagnosis. 
Finally, with respect to choosing a flow cytometry 
scoring system, it must be noted that the parame-
ters of the Ogata system proved to be stable only 
for a day. We suggest verifying beforehand how 
the parameters of the FCSS selected are influ-
enced by the type of anticoagulant and/or delayed 
sample handling. 
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